India’s Torrent Pharma announced in May it had entered into an agreement with the Encore Group to buy the dermatological drugmaker Zyg Pharma, and on Thursday the deal was completed.
The addition sees Torrent support its strategy to strengthen its position in niche dermatologicals in developed markets such as the US and Europe, which it will do through the addition of two manufacturing facilities in Pithampur, Indore, approved by regulators including the US FDA and Asutralia’s TGA.
The site manufactures its own creams, ointments, gels, lotions and solutions for export, as well as having some commercial contract manufacturing space.
Torrent has three existing facilities: an API and finished formulation plant at Indrad in the Gujarat region, an oral dosage form site in Baddi in Himachal Pradesh, and a WHO approved facility in Sikkim. The Indrad plant has been making insulin exclusively for Novo Nordisk for over 15 years.